HLS Therapeutics Inc. (TSE:HLS – Get Free Report)’s share price dropped 7.4% during trading on Thursday. The company traded as low as C$3.75 and last traded at C$3.89. Approximately 388,910 shares traded hands during trading, an increase of 1,077% from the average session volume of 33,030 shares. The stock had previously closed at C$4.20.
Wall Street Analyst Weigh In
HLS has been the topic of a number of recent research reports. Canaccord Genuity Group upgraded shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 13th. Raymond James Financial upgraded shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from C$7.00 to C$8.00 in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. Based on data from MarketBeat, HLS Therapeutics has an average rating of “Strong Buy” and an average price target of C$8.00.
Check Out Our Latest Report on HLS
HLS Therapeutics Trading Down 7.4%
HLS Therapeutics (TSE:HLS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share for the quarter. The business had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative net margin of 15.26% and a negative return on equity of 14.39%. During the same quarter in the previous year, the company posted ($0.09) EPS. As a group, equities analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.
About HLS Therapeutics
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.
See Also
- Five stocks we like better than HLS Therapeutics
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
